John Anderson, MD, gives us a brief introduction to himself and talks about how, as an internal medicine specialist, he deals with a whole range of issues related to diabetes which he see in his patients. More videos with John Anderson, MD: Thoughts on SGLT-2 Inhibitors What is the ADA …

John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

John Anderson, MD, talks about how clinicians should look at more than just a specific A1c number when beginning treatment for diabetes explaining that the measure is really only a way to project future risk. Factors such as family history, ethnic background and other characteristics may be more relevant. But …

Typically when we have discussions about new drugs or drug classes they are not really discussions but presentations by someone on behalf of the manufacturer, and most of the questions are geared to promote the positive aspects of the new medication. In this month’s special edition covering SGLT-2 inhibitors, we …

We know that obesity can lead to diabetes and often we focus on that in prediabetes, but as soon as someone is diagnosed with diabetes we change our focus to treating diabetes, and "live" with the obesity and weight gain. This week, in the final slides of this series by Dr. …

John Anderson, MD, talks about the new SGLT-2 inhibitors, what he has heard so far on their efficacy, and some of the concerns that have been raised about this new class of drugs…. See more SGLT-2 Resources More videos with John Anderson, MD: John Anderson, MD, ADA Board of Directors, …